U.S. drugmakers' quest for tax-friendly foreign addresses could get waylaid by the Treasury Department's efforts to end corporate inversions. The inversions, which involve U.S.-based multinationals moving their tax residence overseas to take advantage of more favorable corporate tax rates, have become a popular theme in the pharmaceutical industry over the past few years, with several companies acquiring addresses in Ireland.